# Quinoline: A Versatile Heterocyclic with Multiple Pharmacological Activities

Izabayo Dieudonne, Bhupinder Kapoor\*, Reena Gupta, Mukta Gupta

School of Pharmaceutical Sciences, Lovely Professional University, Punjab 144401, India

\*Corresponding author Bhupinder Kapoor Associate Professor School of Pharmaceutical Sciences, Faculty of Applied Medical Sciences, Lovely Professional University, Jalandhar-Delhi G.T. Road (NH 1), Phagwara, Punjab (India) - 144411 E mail: bhupipharma@gmail.com

# Abstract

Quinoline is a fused heterocyclic compound containing benzene ring and pyridine ring. It is an important compound due to their versatile applications in the diverse fields including organic & medicinal chemistry. The derivatives of quinoline exhibits multiple therapeutic activities such as antimalarial, anti-inflammatory, anti-asthmatic, anti-bacterial, anti-hypertensive, anti-cancer, anti-viral and anti-amoebic. A number of drugs having quinoline nucleus are available in the market for different therapeutic applications. There are a number of well-established protocols for the synthesis of this heterocyclic ring. This paper summarizes some of the approaches of synthesis of quinoline derivatives having different pharmacological activities.

Key words: Quinoline; 1-Aza-napthalene; Benzo [b] pyridine; Anti-malarial

## **1. Introduction**

Quinoline (1) or benzo[*b*]pyridine or 1-aza-napthalene or 1-benazine is a heterocyclic compound having a single nitrogen atom in the ring. The calculated molecular formula of the compound is C<sub>9</sub>H<sub>7</sub>N which corresponds to molecular weight of 129.16 g/mol. It is a colorless

liquid, which turns yellow on standing and possess a characteristic odour of resembling that of pyridine. It has freezing point of -15.6 °C, boiling point of 237 °C and density 1.097. It is hygroscopic, slightly soluble in cold water but dissolve readily in hot water and most organic solvents [1, 2]. The log P value is 2.04 and has an acidic  $pK_b$  of 4.85 and a basic  $pK_a$  of 9.5. Due to the presence of tertiary nitrogen, quinoline act as weak base and form salt with acids. The chemical properties of quinoline are those that might be anticipated from an amalgamation of those of pyridine and naphthalene. The effect of nitrogen is largely confined to its own ring, which possesses most of the chemical properties of quinoline. Quinoline mainly undergoes addition reaction, ring-opening reaction and substitution reactions (electrophilic and nucleophilic substitution) [3, 4].



Figure 1: Chemical structure of quinoline

A German chemist, Friedlieb Ferdinand Runge, first extracted the quinoline from coal tar in 1834 and it is still the principal source of quinoline [5]. Later on in 1842, French chemist Charles Gerhardt obtained quinoline by heating alkaloids quinine and cinchonine with potassium hydroxide [6, 7]. Quinoline nucleus also occurs in various natural products obtained from plants like *Cinchona officinalis*, *Camptotheca acuminate*, *Ruta graveolensl* and *Haplophyllum dubium* [8]. It was first isolated from bark of bark of the Cinchona tree by Pelletier and Caventou in 1820 and was used in treatment of malarial until 1930. A diastereomer of quinine i.e. quinidine has totally different pharmacological action and is used in treatment of arrhythmia.

Quinoline nucleus possesses a wide range of pharmacological activities such as anti-bacterial, anti-fungal, local anesthetic, anti-asthmatic, anti-cancer, anti-psychotic, anti-glaucoma and anti-malarial. Due to its versatile nature, a number of derivatives of quinoline have been synthesized and are used in clinical practice. Some of the marketed drugs having quinoline nucleus have been listed in **Table 1**.

**Table 1:** Marketed drugs having quinoline nucleus

Comp. No.	Drug	Chemical structure	Therapeutic	Reference
			class	

2	Quinine		Anti-malarial	[9]
3	Pamaquine		Anti-malarial	[10]
4	Chloroquine		Anti-malarial	[11]
5	Mepacrine		Anti-malarial	[9]
6	Amodiaquine		Anti-malarial	[12]
7	Primaquine	H <sub>2</sub> N NH	Anti-malarial	[13]
8	Mefloquine	F F F OH H	Anti-malarial	[14]
9	Pyronaridine		Anti-malarial	[14]

10	Piperaquine	CI	Anti-malarial	[14]
11	Tafenoquine	H <sub>2</sub> N H <sub>2</sub> N N N N N N N N N N N N N N	Anti-malarial	[14]
12	Ciprofloxacin		Anti-bacterial	[15]
13	Sparfloxacin		Anti-bacterial	[15]
14	Gatifloxacin		Anti-bacterial	[15]
15	Cliquinol		Anti-protozoal	[16]
16	Oxamniquine		Anthelmintic	[17]
17	Dibucaine		Local anesthetic	[18]

18	Montelukast	CI NA <sup>+</sup>	Anti-asthmatic	[19]
19	Aripiprazole		Anti-psychotic	[20]
20	Brexpiprazole		Anti-psychotic	[21]
21	Vesnarinone		Cardiotonic	[22]
22	Camptothecin		Anti-cancer	[23]
23	Lenvatinib	$H_2N \xrightarrow{O} \qquad O \qquad$	Anti-cancer	[23]
24	Bosutinib		Anti-cancer	[23]
25	Irinotecan		Anti-cancer	[23]

26	Topotecan		Anti-cancer	[23]
27	Exatecan	F N N F O HO O O	Anti-cancer	[23]
28	Quinidine		Anti-arrhythmic	[24]
29	Saquinavir	$H_2N \leftarrow O_{HN} \qquad H_2 \rightarrow H_1 \rightarrow H_2 \rightarrow H_2 \rightarrow H_1 \rightarrow H_2 \rightarrow H_1 \rightarrow $	Anti-viral	[25]

## 2. Synthetic methods

Quinoline was first synthesized by Skraup over a century ago and thus the method is known as Skraup synthesis. The method is used for the synthesis of many quinoline derivatives, provided the substituents present are unchanged by the reaction conditions. In this method, aniline is heated with glycerol, sulphuric acid and oxidizing agent like nitrobenzene, stannic chloride, ferric salts or arsenic pentoxide [26, 27]. The other approaches for the synthesis of quinoline are Combes synthesis [28], Conrad-Limpach synthesis [29], Doebner-Miller reaction [30], Gould-Jacobs reaction [31], Camps synthesis [32], Friedländer synthesis [33], Knorr synthesis [34], Niementowski synthesis [35], Pfitzinger reaction [36] and Povarov reaction [37]. A number of derivatives of quinolines have been synthesized and some of these studies have been discussed below.

3,4-Dihydroquinolin-2-one derivatives (30), which are difficult to synthesize by intramolecular radical cyclization, had been successfully synthesized from 2-iodoanilines and ethyl acrylate

in neutral reaction conditions by intermolecular tandem reactions involving radical and ionic processes [38].



Figure 2: Intermolecular tandem reaction between 2-iodoanilines and acrylates

An efficient method for the synthesis of 4-alkoxy-2-aryl quinolines (31) had been developed which involve heating of 2-(2-trimethlysiyl) ethynyl) aniline with aromatic aldehydes in alcoholic solvents in the presence of sulphuric acid as catalyst [39].



Figure 3: Sulphuric acid catalyzed cyclization of 2-(2-trimethlysiyl) ethynyl) aniline with aldehydes

Transition-metal free indirect Friedländer synthesis of poly-substituted quinolines (32) had been successfully accomplished by the reaction of 2-aminobenzylic alcohol derivatives with ketones or alcohols in the presence of base [40].

Figure 4: Transition-metal free synthesis of poly-substituted quinolines

2-Phenyl quinoline (33) was synthesized by reacting ethyl vinyl ether or ethyl vinyl sulfide and *N*-arylaldimine in the presence of boron trifluoride etherate to yield 2,4-disubstituted tetrahydroquinolines, which were then converted to 2-phenyl substituted quinolines under vacuum distillation with tosylic acid [41].



Figure 5: Synthesis of 2-Phenyl quinoline

Synthesis of quinoline-4-carboxylic acid derivatives (34) from pyruvic acid, aldehydes and amines in the mild conditions in water had been carried out by Doebner reaction using Ytterbium perfluorooctanoate as catalyst [42].



Figure 6: Synthesis of Quinoline-4-carboxylic acid

The condensation and cyclization of two molecules of *o*-halo acetophenones with urea or primary amines gave halogenated quinolines (35) in catalyst-free conditions. The reported method was the first example of catalyst-free cleavage of  $C(sp^2)$ -X bond and the formation of C-C bond [43].



Figure 7: Reaction of *o*-chloro acetophenone with *n*-propylamine affording quinoline derivative

Ultrasound promoted synthesis of quinolines (36) using basic ionic liquids (BIL) in aqueous media has been reported. The reaction involved condensation of isatin with ketones and is considered to be superior method over conventional synthesis due to requirement of mild reaction conditions, short reaction time and results in high yield of product [44].



Figure 8: Ultrasound promoted synthesis of quinolines (36) using basic ionic liquids (BIL)

#### **3.** Pharmacological actions of quinolines

#### 3.1 Anti-malarial

Malaria is acute, often severe and protracted, disease caused by parasitic protozoa Plasmodium falciparum, P. malariae, P. ovale and P. vivax [45]. A huge number of clinically available antimalarial drug have quinoline nucleus and still this heterocyclic ring is further explored in the search of more potent and less toxic anti-malarial drug.

Two series of novel bisquinoline compounds (37 and 38) that inhibit the growth of both chloroquine-sensitive and chloroquine-resistant strains of *P. falciparum* had been developed by Raynes and his co-workers. Structure activity relationship studies revealed that the optimum chain length for the linker group is 6 carbons and linking through 8-position is better than through the 6-position. The chlorine substituent at 6-position is not required and may be replaced with amide group [46].



Figure 9: Series of novel bisquinoline compounds

A series of 2-Methyl-6-ureido-4-quinolinamides (39) was found to exhibit anti-malarial activity against chloroquine-sensitive *P. falciparum* strain. The derivatives having 3,4-disubstituted phenyl ring elicited better biological activity. Introduction of chloro and amide group were best suited for anti-malarial activity [47]. <sup>[44]</sup>



Figure 10: 2-Methyl-6-ureido-4-quinolinamides derivatives

*In vitro* anti-malarial activity of a new class of hybrid 4-aminoquinoline triazines (40) has been evaluated against chloroquine sensitive strain 3D7 of P. *falciparum*. Compound having piperidine and cyclohexylamine groups was found to be most potent among the different derivatives [48].



Figure 11: 4-Aminoquinoline triazine derivatives

A series of 5-aryl-8-aminoquinoline (41) derivatives were screened for anti-malarial activity in order to distinguish the anti-malarial activity of tafenoquine from its hemolytic side effects. The synthesized compounds were found to be metabolically stable in human and mouse microsomal preparations with potency equal to more than primaquine. Analogues with electron donating groups exhibited better activity that those having electron withdrawing groups [49].



Figure 12: 5-Aryl-8-aminoquinoline derivatives

Anti-malarial potential of hybrid pyridine quinoline molecules (42-44) has been explored in chloroquine sensitive strain of *P. falciparum*. The molecules were found to be very good haem polymerization inhibitors but showed poor antimalarial activity. This was attributed to their low vacuole accumulation ratio in comparison to chloroquine. These molecules can be used as templates for designing new antimalarials targeting haem detoxification pathway of malaria parasite [50].



Figure 13: Pyridine-quinoline bis-quinoline hybrids

The anti-malarial potential of 4-anilinoquinoline ring has been explored by Singh and his coworkers in 2011. All the synthesized derivatives (45) were evaluated for anti-malarial activity by in vitro and in vivo evaluation studies against *P. falciparum* and *P. yoelii*. The compound containing morpholine ring was found to be more potent as compared to other derivatives [51].



R = H, Phenyl, Butyl, Isopropyl, n-Butyl

45

Figure 14: Derivatives of 4-anilinoquinoline ring

#### 3.2 Anti-microbial

Microorganism's resistance to conventional antibiotics is major challenge in the treatment of infectious diseases. A few new anti-microbial agents are available in the market and many are in the clinical development stages. The anti-microbial potential of quinoline molecule has been explored in many of the studies and some of these studies have been discusses briefly here.

Anti-microbial activity of quinoline based heterocyclic compounds have been evaluated against both gram positive and gram negative bacteria as well as against fungi. All the synthesized derivatives exhibited potent antimicrobial activities [52].



46a-f

(a) R=H; R'=NH<sub>2</sub>; (b)R=Cl; R'=NH<sub>2</sub>; (c) R=CH<sub>3</sub>; R'=NH<sub>2</sub>; (d) R=H; R'=H; (e) R=Cl; R'=H; (f) R=CH<sub>3</sub>; R'=H

Figure 15: Anti-microbial activity of synthesized quinoline derivatives

*In vitro* anti-bacterial potential of novel triazolo[4,3-a]quinoline derivatives have been evaluated against both gram positive and gram negative bacteria by agar well diffusion method. The compounds having pyrazole moiety were found to be more potent against gram positive bacteria [53].

#### 3.3 Anti-cancer

5-Oxo-2,4,5,6-tetrahydro-1H-thiopyrano[3,4-c]quinoline-9-carboxamide derivatives, a poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors, were prepared from carboxylic acid and amine and evaluated by cell based assay [54].

#### 4. Conclusion

Quinoline is a versatile nucleus having a wide range of pharmacological activities such as anti-malarial, anti-inflammatory, anti-asthmatic, anti-bacterial, anti-tuberculosis, anti-hypertensive, anti-cancer, anti-HIV and anti-amoebic. Although most of anti-malarial compounds available in the market are based on quinoline nucleus, but this heterocyclic ring exhibits potential in other therapeutic areas also. In order to explore more applications of this nitrogen containing heterocyclic ring, a number of derivatives of quinoline have been synthesized by different group of scientists and evaluated for different pharmacological activities. In many cases, potency of the synthesized compound was found to be comparable to already marked drugs; hence further investigations are required.

#### 5. References

[1] S. Jain, V. Chandra, P.K. Kumar, K. Pathak, D. Pathak and A. Vaidya, "Comprehensive review on current developments of quinoline-based anticancer agents," Arabian J. Chem., Oct. 2016.

[2] L.M. Nainwal, S. Tasneem, W. Akhtar, G. Verma, M.F. Khan, S. Parvez, et al. "Green recipes to quinoline: A review," Eur. J. Med. Chem., vol. 164, pp. 121-170, Feb. 2019.

[3] A. Marella, O.P. Tanwar, R. Saha, M.R. Ali, S. Srivastava, M. Akhter, et al. "Quinoline: A versatile heterocyclic," Saudi Pharm. J., vol. 21, pp. 1-12, Jan. 2013.

[4] R.D. Chambers, D. Holling, G. Sandford, H. Puschmann, J.A.K. Howard, "Selective direct fluorination of quinoline derivatives," J. Fluorine Chem., vol. 117, pp. 99-101, Oct. 2002.

[5] J.B. Bharate, R.A. Vishwakarma, S.B. Bharate, "Metal-free domino one-pot protocols for quinoline synthesis," RSC Adv., vol. 5, pp. 42020-42053, Apr. 2015.

[6] R.H. Manske, "The Chemistry of Quinolines," Chem. Rev., vol. 30, pp. 113-144, Feb. 1942.

[7] S.M. Prajapati, K.D. Patel, R.H. Vekariya, S.N. Panchal, H.D. Patel, "Recent advances in the synthesis of quinolines: a review," RSC Adv., vol. 4, pp. 24463-24476, Apr 2014.

[8] P.Y. Chung, Z.X. Bian, H.Y. Pun, D. Chan, A.S.C. Chan, C.H. Chui, et al. "Recent advances in research of natural and synthetic bioactive quinolines," Future Med. Chem., vol. 7, pp. 947-967, Jun 2015.

[9] R. Thanacoody, "Quinine and chloroquine" Medicine, vol. 44, pp. 197-198, Mar. 2016.

[10] H.Y. Myint, J. Berman, L. Walker, B. Pybus, V. Melendez, J.K. Baird, et al. "Review: Improving the therapeutic index of 8-aminoquinolines by the use of drug combinations: review of the literature and proposal for future investigations," Am. J. Trop. Med. Hyg., vol. 85, pp. 1010-1014, Dec. 2011.

[11] J. Pelt, S. Busatto, M. Ferrari, E.A. Thompson, K. Mody, J. Wolfram, "Chloroquine and nanoparticle drug delivery: A promising combination," Pharmacol. Ther., vol. 191, pp. 43-49, Nov. 2018.

[12] K. Kaur, M. Jain, R.P. Reddy, R. Jain, "Quinolines and structurally related heterocycles as antimalarials," Eur. J. Med. Chem., vol. 45, pp. 3245-3264, Aug. 2010.

[13] B. Zorc, I. Perković, K. Pavić, Z. Rajić, M. Beus, "Primaquine derivatives: Modifications of the terminal amino group," Eur. J. Med. Chem., vol. 182, Aug. 2019.

[14] M. Foley, L. Tilley, "Quinoline antimalarials: mechanisms of action and resistance and prospects for new agents," Pharmacol. Ther., vol. 79, pp. 55-87, Jul. 1998.

[15] M.C. Mandewale, U.C. Patil, S.V. Shedge, U.R. Dappadwad, R.S. Yamgar, "A review on quinoline hydrazone derivatives as a new class of potent antitubercular and anticancer agents,"J. Basic Appl. Sci., vol. 6, pp. 354-361, Dec. 2017.

[16] X. Mao, A.D. Schimmer, "The toxicology of Clioquinol," Toxicol. Lett. vol. 182, pp. 1-6, Nov. 2008.

[17] V.B.R. da Silva, B.R.K.L. Campos, J.F. de Oliveira, J.L. Decout, M.D. Lima M, "Medicinal chemistry of antischistosomal drugs: Praziquantel and oxamniquine," Bioorg. Med. Chem., vol. 25, pp. 3259-3277, Jul. 2017.

[18] Y. Kuroda, M. Ogawa, H. Nasu, M. Terashima, M. Kasahara, Y. Kiyama, et al. "Locations of local anesthetic dibucaine in model membranes and the interaction between dibucaine and a Na+ channel inactivation gate peptide as studied by 2H-and 1H-NMR spectroscopies," Biophys. J., vol. 71, pp. 1191-1207, Sep. 1996.

[19] O. Yilmaz, D. Altintas, C. Rondon, C. Cingi, F. Oghan, "Effectiveness of montelukast in pediatric patients with allergic rhinitis," International Journal of Pediatric Otorhinolaryngology, vol. 77, pp. 1922-1924, Dec. 2013.

[20] D. Naber, M. Lambert, "Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism," Prog. Neuro-Psychopharmacol. Biol. Psychiatry, vol. 28, pp. 1213-1219, Dec. 2004.

[21] F. Corponi, C. Fabbri, I. Bitter, S. Montgomery, E. Vieta, S. Kasper, et al. "Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone," Eur. Neuropsychopharmacol., vol. 29, pp. 971-925, Jun. 2019.

[22] P. Elliott, "Rational use of inotropes," Anaesthesia & Intensive Care Medicine, vol. 7, pp. 326-330, Sep. 2006.

[23] O. Afzal, S. Kumar, M.R. Haider, M.R. Ali, R. Kumar, M. Jaggi, et al. "A review on anticancer potential of bioactive heterocycle quinoline," Eur. J. Med. Chem., vol. 97, pp. 871-910, Jun. 2015.

[24] L.V. Serdoz, H. Rittger, F. Furlanello, D. Bastian, "Quinidine-A legacy within the modern era of antiarrhythmic therapy," Pharmacol. Res., vol. 144, pp. 257-263, Apr. 2019.

[25] D.J. Porche, "Saquinavir," Journal of the Association of Nurses in AIDS Care, vol. 7, pp.61-64, Jul. 1996.

[26] E.W. Cohn, "A modification of the Skraup synthesis of quinoline," J. Am. Chem. Soc., vol. 52, pp. 3685-3688, Sep. 1930.

[27] H.L. Yale, "The Skraup reaction with acrolein and its derivatives. I. The preparation of 6-Methoxy-8-nitroquinoline," J. Am. Chem. Soc., vol. 69, pp. 1230-1230, May 1947.

[28] J.J. Li, "Name Reactions: A Collection of Detailed Mechanisms and Synthetic Applications," Fifth Edition, Springer International Publishing, pp. 155-156, 2014.

[29] J.C. Brouet, S. Gu, N.P. Peet, J.D. Williams, "Survey of solvents for the Conrad–Limpach synthesis of 4-hydroxyquinolones," Synth. Commun. vol. 39, pp. 1563-1569, Apr. 2009.

[30] M. Matsugi, F. Tabusa, J.I. Minamikawa, "Doebner-Miller synthesis in a two-phase system: practical preparation of quinolines," Tetrahedron Lett., vol. 41, pp. 8523-8525, Oct. 2000.

[31] J.J. Li, Gould-Jacobs reaction. In "Name Reactions: A Collection of Detailed Mechanisms and Synthetic Applications," Springer Berlin Heidelberg; pp. 263-265, 2009.

[32] J.J. Li, Camps quinoline synthesis. In "Name Reactions: A Collection of Detailed Mechanisms and Synthetic Applications," Springer International Publishing; pp. 104-105, 2014.

[33] Teimouri A, Najafi Chermahini A, "A mild and highly efficient Friedländer synthesis of quinolines in the presence of heterogeneous solid acid nano-catalyst," Arabian J. Chem., 2016;9:S433-S9.

[34] Y. Wang, C. Chen, J. Peng, M. Li, "Copper(II)-Catalyzed Three-Component Cascade Annulation of Diaryliodoniums, Nitriles, and Alkynes: A Regioselective Synthesis of Multiply

Substituted Quinolines," Angewandte Chemie International Edition vol. 52, pp. 5323-5327, May 2013.

[35] R.J. Chongau, M.A. Siddiqui, V. Snieckus, "Synthetic connections to the aromatic directed metalation reaction. A modified von niementowski quinoline synthesis from anthranilamides," Tetrahedron Lett., vol. 27, pp. 5323-5326, Jan. 1986.

[36] P. Zhou, B. Hu, S. Zhao, Q. Zhang, Y. Wang, X. Li, et al., "An improved Pfitzinger reaction for the direct synthesis of quinoline-4-carboxylic esters/acids mediated by TMSCl," Tetrahedron Lett., vol. 59, pp. 3116-3119, Aug. 2018.

[37] C.R. Borel, L.C.A. Barbosa, C.R.A. Maltha, S.A. Fernandes, "A facile one-pot synthesis of 2-(2-pyridyl)quinolines via Povarov reaction," Tetrahedron Lett., vol. 56, pp. 662-665, Jan. 2015.

[38] W. Zhou, L. Zhang, N. Jiao, "The tandem reaction combining radical and ionic processes: an efficient approach to substituted 3,4-dihydroquinolin-2-ones," Tetrahedron, vol. 56, pp. 1982-1987, Mar. 2009.

[39] Y. Wang, C. Peng, L. Liu, J. Zhao, L. Su, Q. Zhu, "Sulfuric acid promoted condensation cyclization of 2-(2-(trimethylsilyl) ethynyl)anilines with arylaldehydes in alcoholic solvents: an efficient one-pot synthesis of 4-alkoxy-2-arylquinolines," Tetrahedron Lett., Letters vol. 50, pp. 2261-2265, May 2009.

[40] R. Martínez, D.J. Ramón, M. Yus, "Transition-Metal-Free Indirect Friedländer Synthesis of Quinolines from Alcohols," J. Org. Chem., vol. 73, pp. 9778-9780, Oct. 2008.

[41] V.V. Kouznetsov, "Recent synthetic developments in a powerful imino Diels–Alder reaction (Povarov reaction): application to the synthesis of N-polyheterocycles and related alkaloids," Tetrahedron, vol. 14, pp. 2721-2750, Dec. 2009.

[42] L.M. Wang, L. Hu, H.J. Chen, Y.Y. Sui, W. Shen, "One-pot synthesis of quinoline-4carboxylic acid derivatives in water: Ytterbium perfluorooctanoate catalyzed Doebner reaction," J. Fluorine Chem., vol. 130, pp. 406-409, Apr. 2009.

[43] C. Qi, Q. Zheng, R. Hua, "A domino three-component condensation of orthohaloacetophenones with urea or amines: a novel one-pot synthesis of halogen-substituted quinolines," Tetrahedron, vol. 65, pp. 1316-1320, Feb. 2009.

[44] E. Kowsari, M. Mallakmohammadi, "Ultrasound promoted synthesis of quinolines using basic ionic liquids in aqueous media as a green procedure," Ultrason. Sonochem., vol. 18, pp. 447-454, Jan. 2011.

[45] N. Tangpukdee, C. Duangdee, P. Wilairatana, S. Krudsood, "Malaria diagnosis: a brief review," Korean J. Parasitol., vol. 47, pp. 93-102, Jun 2009.

[46] K. Raynes, M. Foley, L. Tilley, L.W. Deady, "Novel bisquinoline antimalarials: Synthesis, antimalarial activity, and inhibition of haem polymerisation," Biochem. Pharmacol., vol. 52, pp. 551-559, Aug. 1996

[47] S. Madapa, Z. Tusi, D. Sridhar, A. Kumar, M.I. Siddiqi, K. Srivastava, et al. "Search for new pharmacophores for antimalarial activity. Part I: Synthesis and antimalarial activity of new 2-methyl-6-ureido-4-quinolinamides," Bioorg. Med. Chem., vol. 17, pp. 203-221, Jan. 2009.

[48] A. Kumar, K. Srivastava, S.R. Kumar, S.K. Puri, P.M. Chauhan, "Synthesis and bioevaluation of hybrid 4-aminoquinoline triazines as a new class of antimalarial agents," Bioorg. Med. Chem. Lett., vol. 18, pp. 6530-6533, Dec. 2008.

[49] H. Shiraki, M.P. Kozar, V. Melendez, T.H. Hudson, C. Ohrt, A.J. Magill, A.J. Lin, "Antimalarial activity of novel 5-aryl-8-aminoquinoline derivatives," J. Med. Chem., vol. 54, pp. 131-142, Dec. 2011.

[50] B.N. Acharya, D. Thavaselvam, M.P. Kaushik, "Synthesis and antimalarial evaluation of novel pyridine quinoline hybrids," Med. Chem. Res., vol. 17, pp. 487-494, Oct. 2008.

[51] B. Singh, D. Chetia, S.K. Puri, K. Srivastava, A. Prakash, "Synthesis and in vitro and in vivo antimalarial activity of novel 4-anilinoquinoline Mannich base derivatives," Med. Chem. Res., vol. 20, pp. 1523-1529, Dec. 2011.

[52] A. Bishnoi, A.K. Tiwari, S. Singh, A. Sethi, C.M. Tripathi, B. Banerjee, "Synthesis, characterization, and biological evaluation of novel thiazole and pyrazole derivatives of quinoline-4-carboxylic acid as potential antimicrobial agents," Med. Chem. Res., vol. 22, pp. 3527-3535, Jul. 2013.

[53] M. Kumar, V. Kumar, G.K. Gupta, "Synthesis, antibacterial evaluation, and SAR study of some novel 3-aryl/heteroaryl-9-methyl-1,2,4-triazolo-[4,3-a]-quinoline derivatives," Med. Chem. Res., vol. 24, pp. 1857-1868, May 2015.

[54] C.H. Park, K. Chun, B.Y. Joe, J.H. Choi, H.C. Lee, I.W. Ku, et al. "Synthesis and evaluation of thiopyrano[3,4-c]quinoline-9-carboxamide derivatives as inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1)," Med. Chem. Res., vol. 21, pp. 1533-1543, Aug. 2012.